Aortitis after switching short-acting granulocyte colony-stimulating factors in a lymphoma patient with HLA-B52.
Aortitis
Diffuse large B-cell lymphoma
Human leukocyte antigen
Short-acting granulocyte colony-stimulating factor
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
23 Mar 2024
23 Mar 2024
Historique:
received:
14
11
2023
accepted:
05
03
2024
revised:
20
02
2024
medline:
24
3
2024
pubmed:
24
3
2024
entrez:
24
3
2024
Statut:
aheadofprint
Résumé
Aortitis is a rare adverse event of granulocyte colony-stimulating factor (G-CSF) treatment. Several previous studies have described recurrent aortitis caused by re-administration of the same G-CSF. However, no previous studies have examined the safety of switching between short-acting G-CSFs in patients who develop aortitis. We report the case of a 55-year-old man with refractory diffuse large B-cell lymphoma, who developed G-CSF-associated aortitis. The aortitis was triggered by filgrastim and recurred after treatment with lenograstim. The patient possessed human leukocyte antigen B52, which has been implicated in Takayasu arteritis. In addition, a drug-induced lymphocyte stimulation test for lenograstim performed upon detection of recurrent G-CSF-associated aortitis produced a positive result. Our case suggests that switching from one short-acting G-CSF to another does not prevent recurrence of G-CSF-associated aortitis. Although the etiology of G-CSF-associated aortitis has not been fully elucidated, our case also suggests that some patients may be genetically predisposed to aortitis.
Identifiants
pubmed: 38521841
doi: 10.1007/s12185-024-03744-w
pii: 10.1007/s12185-024-03744-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science
ID : KAKENHI (21K16248)
Informations de copyright
© 2024. Japanese Society of Hematology.
Références
Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: american society of clinical oncology clinical practice guideline update. J Clin Oncol. 2015;33:3199–212.
doi: 10.1200/JCO.2015.62.3488
pubmed: 26169616
D’Souza A, Jaiyesimi I, Trainor L, Venuturumili P. Granulocyte colony-stimulating factor administration: adverse events. Transfus Med Rev. 2008;22:280–90.
doi: 10.1016/j.tmrv.2008.05.005
pubmed: 18848155
Lee SY, Kim EK, Kim JY, Park TK, Choi SH, Im YH, et al. The incidence and clinical features of PEGylated filgrastim-induced acute aortitis in patients with breast cancer. Sci Rep. 2020;10:18647.
doi: 10.1038/s41598-020-75620-6
pubmed: 33122662
pmcid: 7596224
Hoshina H, Takei H. Granulocyte-colony stimulating factor-associated aortitis in cancer: a systematic literature review. Cancer Treat Res Commun. 2021;29: 100454.
doi: 10.1016/j.ctarc.2021.100454
pubmed: 34530312
Joseph G, Goel R, Thomson VS, Joseph E, Danda D. Takayasu Arteritis: JACC Focus Seminar 3/4. J Am Coll Cardiol. 2022. https://doi.org/10.1016/j.jacc.2022.09.051 .
doi: 10.1016/j.jacc.2022.09.051
pubmed: 36599755
pmcid: 8972366
Oshima Y, Takahashi S, Tani K, Tojo A. Granulocyte colony-stimulating factor-associated aortitis in the japanese adverse drug event report database. Cytokine. 2019;119:47–51.
doi: 10.1016/j.cyto.2019.02.013
pubmed: 30875590
Miller EB, Grosu R, Landau Z. Isolated abdominal aortitis following administration of granulocyte colony stimulating factor (G-CSF). Clin Rheumatol. 2016;35:1655–7.
doi: 10.1007/s10067-016-3253-6
pubmed: 27094941
Sato Y, Kaji S, Ueda H, Tomii K. Thoracic aortitis and aortic dissection following pegfilgrastim administration. Eur J Cardiothorac Surg. 2017;52:993–4.
doi: 10.1093/ejcts/ezx165
pubmed: 28549110
Ito Y, Noda K, Aiba K, Yano S, Fujii T. Diffuse large B-cell lymphoma complicated with drug-induced vasculitis during administration of pegfilgrastim. Rinsho Ketsueki. 2017;58:2238–42.
pubmed: 29212975
Kawahara H, Endo A, Yoshitomi H, Tanabe K. Recurrent granulocyte colony-stimulating factor-induced aortitis after pegfilgrastim administration. Circ Rep. 2020;2:764–5.
doi: 10.1253/circrep.CR-20-0092
pubmed: 33693208
pmcid: 7937525
Shirai T, Komatsu H, Sato H, Fujii H, Ishii T, Harigae H. Migratory aortitis associated with granulocyte-colony-stimulating factor. Intern Med. 2020;59:1559–63.
doi: 10.2169/internalmedicine.4331-19
pubmed: 32188815
pmcid: 7364257
Sasaki K, Miyauchi M, Ogura M, Shimura-Nukina A, Toyama K, Nakazaki K, et al. Arteritis after administration of granulocyte colony-stimulating factor: a case series. Int J Hematol. 2019;110:370–4.
doi: 10.1007/s12185-019-02662-6
pubmed: 31090035
Sasaki K, Matsuda K, Miyauchi M, Honda A, Shimura A, Masamoto Y, et al. A retrospective analysis on arteritis after administration of granulocyte colony-stimulating factor. Ann Hematol. 2021;100:1341–3.
doi: 10.1007/s00277-021-04453-8
pubmed: 33783549
Uemura Y, Oshima K, Fuseya A, Hosokai A, Ohashi A, Kanno M, et al. Aortitis after administration of pegfilgrastim to a healthy donor for peripheral blood stem cell collection. Int J Hematol. 2023. https://doi.org/10.1007/s12185-023-03649-0 .
doi: 10.1007/s12185-023-03649-0
pubmed: 37700187
pmcid: 10673976
Kimura A, Kitamura H, Date Y, Numano F. Comprehensive analysis of HLA genes in Takayasu arteritis in Japan. Int J Cardiol. 1996;54(Suppl):S61–9.
doi: 10.1016/S0167-5273(96)88774-2
pubmed: 9119528
Umeda M, Ikenaga J, Koga T, Michitsuji T, Shimizu T, Fukui S, et al. Giant cell arteritis which developed after the administration of granulocyte-colony stimulating factor for cyclic neutropenia. Intern Med. 2016;55:2291–4.
doi: 10.2169/internalmedicine.55.6704
pubmed: 27523011
Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis. Rheumatology (Oxford). 2006;45:545–8.
doi: 10.1093/rheumatology/kei266
pubmed: 16352633
Parodis I, Dani L, Notarnicola A, Martenhed G, Fernstrom P, Matikas A, et al. G-CSF-induced aortitis: two cases and review of the literature. Autoimmun Rev. 2019;18:615–20.
doi: 10.1016/j.autrev.2018.12.011
pubmed: 30959218